Mark Germain - 01 Jan 2023 Form 3 Insider Report for BiondVax Pharmaceuticals Ltd. (SCNI)

Role
Director, Chairman
Signature
/s/ Mark Germain
Issuer symbol
SCNI
Transactions as of
01 Jan 2023
Net transactions value
$0
Form type
3
Filing time
03 Jan 2023, 14:11:01 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BVXV Stock Options (right to buy) 01 Jan 2023 Ordinary Shares 5,228,400 $0.2150 Direct F1, F2
holding BVXV Stock Options (right to buy) 01 Jan 2023 Ordinary Shares 6,400,000 $0.1740 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock options were granted on May 28, 2019 and have fully vested.
F2 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents four hundred Ordinary Shares.
F3 Stock options were granted on April 6, 2021 and vest in equal monthly installments during a period of four years.